Patents by Inventor Moshe Laudon
Moshe Laudon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240068035Abstract: Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to schizophrenia, autism, attention deficit disorders and Alzheimer's disease based on single nucleotide polymorphisms (SNP) chromosome 2, 2:107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).Type: ApplicationFiled: September 27, 2023Publication date: February 29, 2024Applicant: NEURIM PHARMACEUTICALS (1991) LTD.Inventors: Nava ZISAPEL, Moshe LAUDON
-
Patent number: 11878016Abstract: Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior, hyperactivity, inattention, or Fragile X syndrome or brain neuroinflammation by administering a tablet or liquid or a solid ODT or ODF or SMEDDS containing a ticagrelor or ticagrelor salt or combination with a second agent which may include a magnesium ion containing-compound, a zinc ion containing-compound, a lysine or lysine salt, an arginine or arginine salt, lecithin, or a combination thereof, wherein the ODT or ODF or SMEDDS releases >50% of the ticagrelor or a pharmaceutically acceptable salt thereof and >50% of the second agent within 15 minutes.Type: GrantFiled: October 3, 2022Date of Patent: January 23, 2024Assignee: Neurim Pharmaceuticals (1991) Ltd.Inventors: Nava Zisapel, Moshe Laudon
-
Patent number: 11840731Abstract: Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to Alzheimer's disease, schizophrenia, autism and attention disorders based on single nucleotide polymorphisms (SNP) chromosome 2, 2:107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).Type: GrantFiled: May 10, 2022Date of Patent: December 12, 2023Assignee: NEURIM PHARMACEUTICALS (1991) LTD.Inventors: Nava Zisapel, Moshe Laudon
-
Patent number: 11807907Abstract: Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to Alzheimer's disease, schizophrenia, autism and attention deficit disorders based on single nucleotide polymorphisms (SNP) chromosome 2, 2:107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).Type: GrantFiled: July 28, 2022Date of Patent: November 7, 2023Assignee: NEURIM PHARMACEUTICALS (1991) LTD.Inventors: Nava Zisapel, Moshe Laudon
-
Publication number: 20230105540Abstract: Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior, hyperactivity, inattention, or Fragile X syndrome or brain neuroinflammation by administering a tablet or liquid or a solid ODT or ODF or SMEDDS containing a ticagrelor or ticagrelor salt or combination with a second agent which may include a magnesium ion containing-compound, a zinc ion containing-compound, a lysine or lysine salt, an arginine or arginine salt, lecithin, or a combination thereof, wherein the ODT or ODF or SMEDDS releases >50% of the ticagrelor or a pharmaceutically acceptable salt thereof and >50% of the second agent within 15 minutes.Type: ApplicationFiled: October 3, 2022Publication date: April 6, 2023Applicant: NEURIM PHARMACEUTICALS (1991) LTD.Inventors: Nava ZISAPEL, Moshe LAUDON
-
Publication number: 20220389508Abstract: Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to Alzheimer's disease, schizophrenia, autism and attention deficit disorders based on single nucleotide polymorphisms (SNP) chromosome 2, 2:107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).Type: ApplicationFiled: July 28, 2022Publication date: December 8, 2022Applicant: NEURIM PHARMACEUTICALS (1991) LTD.Inventors: Nava ZISAPEL, Moshe LAUDON
-
Publication number: 20220364172Abstract: Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to Alzheimer's disease, schizophrenia, autism and attention disorders based on single nucleotide polymorphisms (SNP) chromosome 2, 2:107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).Type: ApplicationFiled: May 10, 2022Publication date: November 17, 2022Applicant: NEURIM PHARMACEUTICALS (1991) LTD.Inventors: Nava ZISAPEL, Moshe LAUDON
-
Patent number: 10869857Abstract: The instant invention is generally directed to a patient-friendly drug delivery system for targeted populations, such as pediatric and geriatric patients. Specifically, the present invention relates to a pharmaceutical composition in the form of mini-tablets. Even more specifically, the present invention relates to a pharmaceutical composition comprising a therapeutically-effective amount of melatonin in the form of mini-tablets.Type: GrantFiled: June 16, 2020Date of Patent: December 22, 2020Assignee: Neurim Pharmaceuticals Ltd.Inventors: Moshe Laudon, Nava Zisapel
-
Patent number: 10849856Abstract: A patient-friendly drug delivery system and method for targeted populations, such as pediatric and geriatric patients is provided, which system and method include a pharmaceutical composition in the form of mini-tablets. A method of inducing and maintaining sleep in a human in need thereof with the mini-tablets is provided. A method of manufacturing mini-tablets is provided.Type: GrantFiled: June 16, 2020Date of Patent: December 1, 2020Assignee: Neurim Pharmaceuticals Ltd.Inventors: Moshe Laudon, Nava Zisapel
-
Publication number: 20200306227Abstract: The instant invention is generally directed to a patient-friendly drug delivery system for targeted populations, such as pediatric and geriatric patients. Specifically, the present invention relates to a pharmaceutical composition in the form of mini-tablets. Even more specifically, the present invention relates to a pharmaceutical composition comprising a therapeutically-effective amount of melatonin in the form of mini-tablets.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Applicant: NEURIM PHARMACEUTICALS LTD.Inventors: Moshe LAUDON, Nava ZISAPEL
-
Publication number: 20200306193Abstract: A patient-friendly drug delivery system and method for targeted populations, such as pediatric and geriatric patients is provided, which system and method include a pharmaceutical composition in the form of mini-tablets. A method of inducing and maintaining sleep in a human in need thereof with the mini-tablets is provided. A method of manufacturing mini-tablets is provided.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Applicant: NEURIM PHARMACEUTICALS LTD.Inventors: Moshe LAUDON, Nava ZISAPEL
-
Patent number: 10722494Abstract: The instant invention is generally directed to a patient-friendly drug delivery system for targeted populations, such as pediatric and geriatric patients. Specifically, the present invention relates to a pharmaceutical composition in the form of mini-tablets. Even more specifically, the present invention relates to a pharmaceutical composition comprising a therapeutically-effective amount of melatonin in the form of mini-tablets.Type: GrantFiled: October 31, 2018Date of Patent: July 28, 2020Assignee: Neurim Pharmaceuticals Ltd.Inventors: Moshe Laudon, Nava Zisapel
-
Publication number: 20190175554Abstract: The invention relates to a medicament for treating pruritus and itch in a patient suffering from dermatological and non-dermatological conditions leading to such symptoms, which comprises at least one compound selected from a pyrone-indole derivative, in an effective amount, and optionally one or more other therapeutically active agents.Type: ApplicationFiled: June 30, 2017Publication date: June 13, 2019Applicant: Neurim Pharmaceuticals (1991) Ltd.Inventor: Moshe LAUDON
-
Publication number: 20190060277Abstract: The instant invention is generally directed to a patient-friendly drug delivery system for targeted populations, such as pediatric and geriatric patients. Specifically, the present invention relates to a pharmaceutical composition in the form of mini-tablets. Even more specifically, the present invention relates to a pharmaceutical composition comprising a therapeutically-effective amount of melatonin in the form of mini-tablets.Type: ApplicationFiled: October 31, 2018Publication date: February 28, 2019Applicant: NEURIM PHARMACEUTICALS LTD.Inventors: Moshe LAUDON, Nava ZISAPEL
-
Patent number: 9416166Abstract: There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof.Type: GrantFiled: March 27, 2015Date of Patent: August 16, 2016Assignee: Neurim Pharmaceuticals (1991) Ltd.Inventors: Elhanan Pinner, Moshe Laudon, Nava Zisapel
-
Publication number: 20150266940Abstract: There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof.Type: ApplicationFiled: March 27, 2015Publication date: September 24, 2015Inventors: Elhanan Pinner, Moshe Laudon, Nava Zisapel
-
Patent number: 9119846Abstract: The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist.Type: GrantFiled: September 10, 2014Date of Patent: September 1, 2015Assignee: Neurim Pharmaceuticals (1991) Ltd.Inventors: Nava Zisapel, Moshe Laudon
-
Patent number: 9101613Abstract: Neurological disorders and diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Down's syndrome, can be ameliorated or beneficially treated by administration of a formulation comprising an effective amount of a pyrone-indole derivative of formula (I) Ar—B—Ar???(I) wherein AR represents an indole nucleus ring system: Ar? represents an alpha-, beta- or gamma-pyrone nucleus ring system: and each of B, R1, R2, R3, R4, R1? and R2? are as defined herein.Type: GrantFiled: August 12, 2013Date of Patent: August 11, 2015Assignee: Neurim Pharmaceuticals (1991) Ltd.Inventors: Moshe Laudon, Tal Peleg-Shulman
-
Patent number: 9018180Abstract: There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence being at least 90% homologous to at least 20 nucleotides of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or any combination thereof. There is further provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression and/or activity of a polypeptide, wherein the sequence of the polypeptide is selected from a group that includes a contiguous amino acid sequence being at least 90% homologous to at least 10 amino acid of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or any combination thereof.Type: GrantFiled: July 10, 2008Date of Patent: April 28, 2015Assignee: Neurim Pharmaceuticals (1991) Ltd.Inventors: Elhanan Pinner, Moshe Laudon, Nava Zisapel
-
Publication number: 20140378512Abstract: The invention relates to a pharmacologically active combination, having utility in treating insomnia patients, which comprises: (a) at least one first active ingredient selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists; and (b) at least one second active ingredient selected from nicotine and nicotine receptor agonists; to use of a medicament containing component (a) with or without component (b) for alleviation of at least one adverse effect which occurs in a patient in the course of nicotine replacement therapy, or otherwise, selected from impairment of the quality of sleep, impairment of cognition and impairment of memory, as well as to a kit having utility in treating insomnia patients, which comprises components (a) and (b) in unit dosage form.Type: ApplicationFiled: September 10, 2014Publication date: December 25, 2014Applicant: NEURIM PHARMACEUTICALS (1991) LTD.Inventors: Nava ZISAPEL, Moshe LAUDON